Authors:

Juan Ybarra

Clínica CIMA, Centro Médico Teknon, C/Vilana 1208025 Barcelona, Spain.

Abstract:

Background: In order to give and anticipate secondary prevention measures as well as strengthen action on risk factors, particularly in primary care, it is crucial to identify patients who are at risk of developing diabetic peripheral neuropathy (DPN). It’s noteworthy that nobody knows how common DPN is where we live. Aims: 1) to examine ACE gene polymorphisms as a genetic marker of risk of developing DPN, and 2) to ascertain the prevalence of DPN in our environment. Research design and methods:a three-year longitudinal prospective cohort study with a randomly chosen sample of T2DM patients (N=283). Distribution of ACE gene polymorphisms (I=insertion; D=deletion) was identified. Using clinical and neurophysiological testing, DPN was identified. Conclusions: Heterozygous ACE polymorphism (D/I) is a protective factor for DPN development in our dataset. DPN’s cumulative incidence was important. More prospective research is required.

Keywords:
Type 2 diabetes mellitus (T2DM); Angiotensin converting enzyme (ACE); Gene polymorphism; Diabetic peripheral neuropathy (DPN)

Citation:

Juan Ybarra. Longitudinal Prospective Study on the Angiotensin Converting Enzyme Gene Polymorphism as aGenetic Biomarker of Diabetic Peripheral Neuropathy. Clinical Imaging and Case Reports 2022.